1 · The market is an oligopoly — and that is the whole point
UK first-opinion vetcare has been rolled up faster than almost any country on earth. A handful of groups — the “Big 6” — now own a large share of clinics, most of them backed by private equity (PE) or global corporates. They usually keep the original local name on the door, because their own surveys show clients barely care who owns the practice — so you often cannot tell a corporate from an independent without checking the company register. That opacity is a feature, not an accident.
IVC EvidensiaEQT, Silver Lake, Nestlé (PE)£3.5bn rev · £694m EBITDA (~20%)
The largest group on earth. ~1,000 UK sites; central focus of the CMA review.
VetPartnersBC Partners (PE)£861m rev · £158m EBITDA (~18%)
Goddard in London. “Run by vets for vets”; highest staff-review score of the PE groups.
CVS GroupPublicly listed (LSE: CVSG)£673m rev · £136m EBITDA (~20%)
Listed, so the most transparent. Healthy Pet Club locks in recurring revenue.
MedivetCVC Capital Partners (PE)£410m rev · £76m EBITDA (~19%)
Biggest London footprint; many small neighbourhood sites feeding a 24h hub.
Mars (Linnaeus)Mars, Incorporated (family-owned)Part of a ~£35bn+ global group
Not PE, so no buyout debt. Linnaeus/Village Vet: premium & referral, the most advanced-qualified teams.
Pets at Home (Vets4Pets)Pets at Home Group plc (listed)~£1.5bn group rev
Joint-venture model: each site part-owned by a vet (a JV Partner) — a real route to ownership.
Group financials: Gain.pro Veterinary Services Europe, FY24–25. Margins are EBITDA as a share of revenue.
Our read: the kept-name strategy is the single most important thing for a vet to understand, because it quietly removes the information you would normally use to judge an employer or a competitor. When you cannot tell from the outside whether a clinic is an owner-run independent or one site in a thousand-clinic PE group, you cannot tell whose targets set your rota, who really decides your pay, or who you are actually negotiating against. We think the consolidation itself is neither sinister nor surprising — vetcare is a fragmented, cash-generative, recession-resistant sector, exactly what financial buyers look for. The thing worth your attention is not that it happened but that it is invisible. Most of this site exists to put that information back in your hands.
2 · The roll-up playbook — how your clinic becomes someone’s “asset”
Consolidation runs on a repeatable recipe. It is worth understanding even if you never sell, because it shapes who you compete with and who will one day knock on your door. The classic target is an independent whose owner is nearing retirement with no successor — exactly the practices this site flags with a succession signal.
1Buy at a multiple of EBITDA. Clinics change hands at roughly 9–10× EBITDA (the annual profit before interest, tax and accounting wear-and-tear). So a clinic making £300k a year can be worth ~£2.7–3m. Analogy: the multiple is the prognosis — what the buyer thinks the “patient” will earn for years, paid up front.
2Load it with debt. The buyer puts in some equity and borrows the rest — often ~5× EBITDA in loans — secured against the business. The clinic’s own cash flow then services that debt. More sites, more debt, more pressure on each consult to pay it back.
3Split the building from the business (OpCo/PropCo). If the practice owns its premises, the buyer often separates the property company (PropCo) from the operating company (OpCo), sells or mortgages the building, and the clinic then pays rent to its own landlord. Cash is pulled out today; a rent bill arrives forever.
4Keep the founders on a leash. “Earn-outs” and “rollover equity” (you keep, say, 20%) hold back part of your money for 2–3 years, tied to hitting targets — so you keep working to the new owner’s plan after you’ve “sold”.
5Hide the profit, keep the name. Reported profit looks small because of goodwill amortisation (an accounting charge for what they overpaid) and interest — useful at tax time and when arguing margins to a regulator. The local name stays on the door so clients never notice the change.
Mechanics are standard private-equity practice in this sector (illustrative, generalised). Multiples and leverage per public deal commentary and Gain.pro.
Our read: the part that catches vets out is step 4. By the time you have “sold”, you usually haven’t — a chunk of your money is parked in an earn-out or rollover equity that only pays out if the new owner’s targets are hit, on the new owner’s timetable, using levers (pricing, staffing) you no longer fully control. We’d treat any headline price as two numbers: the bit you actually bank on day one, and the bit you are lending back to the buyer in the hope it materialises. The second number is where the risk lives, and it is the first thing we’d pin down in writing.
3 · How the money is really made — and where you get squeezed
A vet clinic earns on price × volume × mix. Understanding that one line tells you where every “efficiency” conversation is really heading.
Gross margin ~77%. Once the building and team are paid for, most of each extra pound of revenue drops through. That is why owners are pushed on average transaction value (the average bill) and on doing more per visit.
Pharmacy / medicines. Selling medications has historically been a fat slice of profit, often higher-margin than the consult itself. This is precisely what the CMA is targeting (see below).
Preventative plans. Monthly health-plan memberships are gold: recurring, predictable revenue that makes a clinic look like a subscription business and lifts its sale multiple.
Locums. Agency locums are the relief valve for the vet shortage — and the biggest controllable cost. “Reduce locum reliance” is the number-one line in almost every turnaround plan. Analogy: locum spend is the fluid loss — until you measure hours × £, any recovery plan is guesswork.
Our read: when a manager talks about “growth”, they almost always mean one of three things — lift the average bill, add a recurring plan, or cut locum hours. None of those are inherently bad medicine; a health plan that gets a dog its dental done is a genuine win. But the same levers, pushed too hard against a debt repayment schedule, are exactly how clinical decisions start bending towards revenue. The tell, in our experience, is whether the targets are framed around health outcomes or around transaction value. Ask which, in an interview — the answer tells you a lot about who really runs the room.
£ · What the work pays — and why you should always benchmark
Pay here is not set by the badge on the door; it is set site by site, and the vet shortage gives you more leverage than the profession’s old culture admits. From 552 live London job adverts (Vet Times, June 2026), the medians are:
Veterinary surgeon
£65kmedian · £60–70k · 446 ads
Senior / lead vet
£75kmedian · £70–80k · 63 ads
OOH / Emergency vet
£40kmedian · £35–69k · 43 ads
Our read: treat these as your anchor. Because pay is set per site and not per brand, the only way to know whether an offer is fair is to compare it with the live market — and the shortage means a good vet has more room to negotiate than they think. On the Ownership models page we break pay down by group; this is the market it should be measured against.
Benchmark a specific offer →
Source: 552 live UK/London veterinary job adverts, Vet Times, June 2026 (vet roles only).
4 · The CMA review, in plain English
The Competition and Markets Authority has been investigating UK vetcare since 2023. What it means for you:
- No price caps. Nobody is capping fees — caps don’t work when there aren’t enough vets. Instead the lever is transparency: publish prices for core services so clients can compare.
- Prescriptions can walk. Clients must be told they can buy medicines elsewhere. That directly threatens the high-margin pharmacy income above — a real squeeze on the groups that relied on it.
- More admin. Website pricing, disclosures, compliance — cheap for a big group with central functions, a real drag for a single independent.
- Forced divestments. The CMA has already made groups sell clinics (e.g. Medivet and IVC divestitures) where local dominance was too high — which is how independents occasionally get a rare shot to buy a site.
Sources: CMA veterinary market investigation working papers & hearings, 2024–26; BVA.
Our read: there is a real irony here. The transparency and compliance burden the CMA is creating is trivial for a group with a central pricing and legal function, and genuinely painful for a sole-owner independent doing it on a Sunday evening. So a remedy aimed at curbing the consolidators may, at the margin, make life harder for exactly the independents who are the alternative to them. The bit we’d actually watch is the medicines income: if prescriptions really do start walking out the door, a meaningful slice of the profit the whole roll-up was priced on starts to thin — and that, more than any fine, is what could reshape what these groups are willing to pay for the next clinic.
5 · If they offer to buy your clinic — or make you a “Branch Partner”
Groups invite vets to “partner” or buy in with a polished forecast deck. Read it like a referral letter that says “patient is stable” with a treatment plan — but no lab results. It is a story and a prognosis, not the raw data you need to verify the diagnosis. Before you sign anything, demand the “tests”:
1. The transaction spine (anonymised): every month, by procedure code — units, net price, discount flag, which vet. This is the CBC/biochem panel of the business: it separates price, volume and mix, and shows real discounting.
2. Monthly P&L with staff & locum split — revenue, costs, vet payroll vs locum hours & £. The haemodynamics: where the cash actually bleeds.
3. Locum hours × £ and agency fees — without it any “we’ll cut locums” promise is guesswork.
4. The lease pack — lease, rent reviews, service charges. Confirms the rent step-up baked into their forecast (and any PropCo rent).
5. Top-20 price list + discount policy — verifies today’s prices before you accept any “we’ll raise the average bill” uplift.
6. COGS by category — confirms margins and whether supplier rebates are really flowing.
You are allowed to do this. Under a normal NDA you can share these figures with your own accountant or adviser — that is what advisers are for. Privacy law (GDPR) only stops you sharing client identities, not anonymised business totals. Ask for a privacy-safe data pack; offer a short data-processing addendum and secure transfer. A “sensitive / not relevant right now” brush-off is itself information.
Watch the structure, not just the price. A high headline number can hide an earn-out that traps your money, rollover equity you can’t sell, or a PropCo rent that eats the clinic alive. Get the multiple, the debt, the rent and the earn-out terms in writing before the number seduces you.
6 · Where we think this is heading — our view
This section is openly interpretive: it is how we read the direction of travel, not settled fact. We think four things are happening at once, and together they decide how much room a working vet will have over the next few years.
aThe easy roll-up is over. The cheap, obvious independents have largely been bought. We expect fewer, more expensive deals and more competition between the groups for the clinics that remain — which keeps prices for good independents high, and makes a credible individual buyer more interesting to a retiring owner than they were five years ago.
bThe debt has to be refinanced. Buyouts done in a cheaper-money era eventually have to roll their loans over at today’s rates. We’d expect that to show up as tighter cost control, more centralisation, and the occasional site being sold or closed — visible to you as rota pressure and reorganisations, not headlines.
cThe CMA changes the maths, slowly. If medicines income thins and price transparency bites, the profit the next clinic is valued on gets harder to defend. We don’t expect a crash — just that the groups become choosier, and that some forced divestments hand independents rare chances to buy.
dThe vet shortage is the real power. Through all of it, the binding constraint is that there are not enough vets. That is your leverage. A model that depends on lean staffing cannot afford to lose you cheaply — which is exactly why benchmarking your pay and naming your terms works better now than the profession’s old culture pretends.
What this means for your career. You don’t have to fight the consolidation to benefit from understanding it. Three practical moves fall out of the above: (1) treat the brand as cosmetic — judge a job by its rota, targets and the person you report to, which you can probe in an interview; (2) benchmark relentlessly — the shortage is on your side, and the live medians on Explore give you a number to anchor to; and (3) if ownership appeals at all, start early — the single highest-leverage thing a vet can do is be in conversation with a good retiring-owner independent before a group is the only buyer at the table. That is the gap this site is built to help you find.
Plain-English glossary
EBITDA Earnings before interest, tax, depreciation & amortisation — roughly the clinic’s underlying annual profit. The number everything is priced off.
Multiple (EV/EBITDA) How many years of EBITDA the buyer pays. 9× EBITDA = price is nine times annual profit.
Leverage Borrowed money used to buy the business. “5× leverage” = debt of five times EBITDA, repaid out of the clinic’s cash.
Goodwill / amortisation The premium paid above a business’s tangible worth, then written down each year as a paper cost — shrinks reported profit without touching cash.
OpCo / PropCo Splitting the operating business from the property that owns the building, so the building can be sold/mortgaged and rented back.
Locum A temporary vet hired (often via agency) to fill gaps — flexible but expensive; the main swing cost.
JV Partner / Branch Partner A vet who part-owns and runs one site under a group’s brand (Vets4Pets JVP, Medivet Branch Partner). Real ownership, but inside the group’s system.
ERV Estimated rental value — the market rent a surveyor thinks the premises should command; drives rent-review increases.
Average transaction value The average bill per visit. Pushing it up is the quiet lever behind most “growth” plans.
Preventative / health plan Monthly membership for routine care — valuable because it is recurring, predictable revenue.
